TransCode Therapeutics Inc. Common Stock

TransCode Therapeutics Inc. a ribonucleic acid (RNA) oncology company focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b a master regulator of metastatic cell viability in a range of cancers including breast pancreatic ovarian colon cancer glioblastomas and others. The company is also developing TTX-siPDL1 an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition the company developing TTX-RIGA an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics Inc. was incorporated in 2016 and is based in Boston Massachusetts.